<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150205020965N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-11</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of date seed powder on diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of  date seed powder supplementation on nutritional status, metabolic, oxidative stress and inflammatory parameters in diabetes type 2 patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>42</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58044</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: At baseline, eligible individuals will be matched for BMI and age according to the classification of these variables. Individuals will be randomly divided into two groups, the intervention group (n=21, receiving date seed powder) control (n=21, receiving Maltodextrin) using RAS software into 2 and 4 blocks, and will be given codes 1 and 2, Blinding description: After randomization, both groups will be given date seed powder and maltodextrin that encoded in sachets weighing 2.5 g in similar packages (metalized) without the researcher intervention and coded with codes 1 and 2. Until releasing of study results, the patient, the researcher, and the data analyzer will not be aware of the assigned codes. Therefore, the study will be three-blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: date seed powder. This group will consume two sachets of 2.5 g of date seed powder (Flavinea Company, Iran) daily for 2 months in the morning and evening in food such as drinks or yogurt. Intervention 2: Control group: maltodextrin. The group will consume two sachets of 2.5 g of maltodextrin (Qinhuangdao Lihua Starch co, china) daily for two months in the morning and evening in foods such as beverages or yogurt.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Participant data will be presented in the article without identifiable details

When:
2022-2023

To whom:
Tabriz University of Medical Sciences

Conditions:
The application must be submitted to Tabriz University of Medical Sciences. It will available if Tabriz University of Medical Sciences is allowed.

Where to obtain:
Tabriz University of Medical Sciences

How to obtain:
The application must be submitted to Tabriz University of Medical Sciences. It will available if Tabriz University of Medical Sciences is allowed.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parvin Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz University Of Medical Sciences,  Nutrition Faculty, Attar Neyshabori Street, Golghash street.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3335 7581</telephone>
        <email>dehghan.nut@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parvin Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Attar Neyshabori Street, Golghash street, Nutrition Faculty, Tabriz University Of Medical Sciences,</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3335 7580</telephone>
        <email>dehghanp@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Have at least 6 months of diabetes history
No weight changes during the last 3 months
No insulin therapy
Use of blood sugar lowering drugs
Tendency to consume palm kernel powder during the study
Having a BMI between 25 and 35</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Use of glucocorticoids, laxatives, anti-obesity, multivitamins, nonsteroidal anti-inflammatory drugs (NSAIDS) and antibiotics
Take antioxidant supplements at least three months before the start of the study
History of weight loss diet in the last 6 months or special diet
Having diseases such as intestinal diseases such as inflammation of the intestines, intestinal cancer and digestive problems
Having thyroid disorders, heart disease, kidney, liver, lung, infectious and other cancers treated with radiotherapy
Alcohol or smoking
Pregnancy, breastfeeding, being an athlete or doing strenuous physical activity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: date seed powder. This group will consume two sachets of 2.5 g of date seed powder (Flavinea Company, Iran) daily for 2 months in the morning and evening in food such as drinks or yogurt.</i_keyword>
      <i_keyword>Control group: maltodextrin. The group will consume two sachets of 2.5 g of maltodextrin (Qinhuangdao Lihua Starch co, china) daily for two months in the morning and evening in foods such as beverages or yogurt.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Lipid profile (TG, TC, HDL-c). Timepoint: At baseline and and two months after the start of the study. Method of measurement: Kit.</prim_outcome>
      <prim_outcome>Total antioxidant capacity. Timepoint: At baseline and two months after start of the study. Method of measurement: Kit.</prim_outcome>
      <prim_outcome>Malondialdehyde. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>Tumor Necrosis Factor(TNF). Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>Highly sensitive C-reactive protein(hs-CRP ). Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>HbA1c. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>Fasting glucose. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>Fasting insulin. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>Interleukins 4, 6, 10, 18. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Fructosamine. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>LPS endotoxin. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Pentosidine. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Total oxidant status (TOS). Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>Carboxymethyl lysine (CML). Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Soluble receptor for advanced glycation end-products. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>8-iso-prostaglandin F2α. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Brain-derived neurotrophic factor. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Cortisol. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Tryptophan. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Kynurenine. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Adrenocorticotropic hormone. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>Adipokines (leptin and adiponectin). Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.</prim_outcome>
      <prim_outcome>T lymphocyte ( CD4 and CD8). Timepoint: At baseline and two months after start of the study. Method of measurement: flow cytometry.</prim_outcome>
      <prim_outcome>Glutathione peroxidase. Timepoint: At baseline and two months after start of the study. Method of measurement: Kit.</prim_outcome>
      <prim_outcome>Superoxide dismutase. Timepoint: At baseline and two months after start of the study. Method of measurement: Kit.</prim_outcome>
      <prim_outcome>Catalase. Timepoint: At baseline and two months after start of the study. Method of measurement: Kit.</prim_outcome>
      <prim_outcome>Uric acid. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
      <prim_outcome>8-Hydroxy-2-deoxy-guanosine. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body Mass Index (BMI). Timepoint: At baseline and two months after baseline. Method of measurement: Scale-Meter.</sec_outcome>
      <sec_outcome>Energy intake,  Daily macronutrient intake (carbohydrate, protein, fat). Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>General Health , Sleep quality, Depression, Anxiety and Stress. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: At baseline and two months after baseline. Method of measurement: manometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-16</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Tabriz University Of Medical Sciences, Nutrition Faculty, Attar Neyshabori Street, Golghash street. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
